Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Nuveen Asset Management LLC lessened its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 50.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 355,057 shares of the company's stock after selling 360,243 shares during the period. Nuveen Asset Management LLC owned 0.25% of Denali Therapeutics worth $7,236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Rhumbline Advisers raised its position in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the period. PNC Financial Services Group Inc. raised its holdings in Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares during the period. Sterling Capital Management LLC lifted its position in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Denali Therapeutics by 0.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock valued at $4,250,000 after purchasing an additional 1,702 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its position in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Trading Down 0.2%

NASDAQ DNLI traded down $0.03 on Tuesday, hitting $13.93. 2,071,936 shares of the company's stock were exchanged, compared to its average volume of 1,118,596. The stock has a 50-day moving average of $13.84 and a 200-day moving average of $18.34. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -5.05 and a beta of 1.49. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the business earned ($0.68) earnings per share. As a group, analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on DNLI. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Morgan Stanley initiated coverage on Denali Therapeutics in a report on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Bank of America decreased their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Wedbush lowered their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.